Rémy Henri Luthringer
Chief Executive Officer at MINERVA NEUROSCIENCES, INC.
Net worth: 449 110 $ as of 2024-04-29
Network origin in Rémy Henri Luthringer first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 25 | |
Index Ventures SA
 Index Ventures SA Investment ManagersFinance Index Ventures SA (Index Ventures) is a venture capital firm founded in 1996 by Neil Alexander Rimer, Gluseppe Zocco and Gerald Rimer. The firm is headquartered in Geneva, Switzerland.
20
| Private Company | Investment Managers | 20 |
Orexia Therapeutics Ltd.
 Orexia Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Orexia Ltd. develop orally administered orexin positive modulators for the treatment of neurological diseases. The company was founded on October 5, 2018 and is headquartered in London, the United Kingdom.
2
| Subsidiary | Miscellaneous Commercial Services | 2 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Rémy Henri Luthringer via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
| ARQULE, INC. | Pharmaceuticals: Major | Investor Relations Contact | |
| AMARIN CORPORATION PLC | Pharmaceuticals: Major | Comptroller/Controller/Auditor Director/Board Member | |
ViaCell, Inc.
 ViaCell, Inc. Medical SpecialtiesHealth Technology ViaCell, Inc. provides and develops cellular medicine for the treatment of diseases. The firm develops medicines for treatment of cancer, genetic disorders, organ transplant tolerance, neurological disorders, and autoimmune diseases. The company was founded in April 2000 and is headquartered in Cambridge, MA. | Medical Specialties | Director/Board Member Chief Executive Officer | |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Medical Specialties | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| SANOFI | Biotechnology | Corporate Officer/Principal | |
| University of Notre Dame | College/University | Undergraduate Degree Corporate Officer/Principal | |
| AEGERION PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
| TIGENIX NV | Medical Specialties | Director/Board Member | |
NormOxys, Inc.
 NormOxys, Inc. Pharmaceuticals: MajorHealth Technology NormOxys, Inc. develops small-molecule therapeutics for the treatment of cancer. Its major product is OXY111A. The company was founded by Conrad J Bletzer, Jr. Claude Nicoalu, Jean-Mearie Lehn, Gay Goodman, Ruth Greferath and Roscoe Brady in 2004 and is headquartered in Brighton, MA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Undergraduate Degree Masters Business Admin | |
| Imperial College London | College/University | Undergraduate Degree Doctorate Degree | |
Limburgse Reconversie Maatschappij NV
 Limburgse Reconversie Maatschappij NV Investment ManagersFinance Limburgse Reconversie Maatschappij NV (LRM) is an independent private equity firm which was founded in 1994 by the Flemish government. Limburgse Reconversie Maatschappij NV is headquartered in Hasselt, Beglium. | Investment Managers | Private Equity Investor | |
| Massachusetts Institute of Technology | College/University | Undergraduate Degree Doctorate Degree | |
| Boston College | College/University | Undergraduate Degree Undergraduate Degree | |
| INSEAD | College/University | Masters Business Admin Masters Business Admin | |
| University of New Hampshire | College/University | Graduate Degree | |
| Federal University of Rio de Janeiro | College/University | Doctorate Degree | |
| Hasselt University | College/University | Graduate Degree | |
OncoEthix SA
 OncoEthix SA Pharmaceuticals: MajorHealth Technology OncoEthix SA operates as a clinical stage biotechnology company which develops cancer drugs. Its products include OTX008, OTX015, and OTX009. The company was founded by Esteban Cvitkovic, Jeanne Kay Noel, Yves Paternot, and Patrice Herait in March 2007 and is headquartered in Luzern, Switzerland. | Pharmaceuticals: Major | Director/Board Member | |
Bristol-Myers Squibb SARL
 Bristol-Myers Squibb SARL Medical DistributorsDistribution Services Bristol-Myers Squibb SARL engages in the research, development, manufacture, and distribution of pharmaceutical products. Its therapeutic areas include immunoscience, immune-oncology, and cardiology. The company is headquartered in Rueil-Malmaison, France. | Medical Distributors | Corporate Officer/Principal | |
| NOVOCURE LIMITED | Medical Specialties | Chairman Director/Board Member | |
Apitope Technology (Bristol) Ltd.
 Apitope Technology (Bristol) Ltd. Miscellaneous Commercial ServicesCommercial Services Apitope Technology (Bristol) Ltd. is a European biotech company developing therapeutic vaccines for treating autoimmune and allergic diseases, including multiple sclerosis, Type 1 diabetes, Graves' disease, allergies and organ transplant rejection. The team at Apitope is developing potential therapies intended to selectively treat the underlying cause of a range of autoimmune diseases rather than simply treat the disease symptoms or non-specifically suppress the whole immune system. Apitope's approach is based on well-established scientific evidence published in leading scientific journals showing that soluble, synthetic peptides can selectively suppress abnormal immune responses and reinstate the normal immune balance and thereby, tolerance. The firm's strategy is to position itself as a significant player in the therapeutic peptide space and make it a partner of choice for pharmaceutical companies keen to develop disease modifiers for autoimmune conditions. It has a highly experienced senior management team, with a proven track record in discovering and developing innovative compounds. The company's lead product candidate is under investigation for the potential treatment of multiple sclerosis and is currently in Phase I clinical development. It is partnered with Merck-Serono (a division of Merck KGaA, Darmstadt, Germany), one of the leading companies in the development and marketing of MS therapies. | Miscellaneous Commercial Services | Director/Board Member | |
ProFibrix BV
 ProFibrix BV BiotechnologyHealth Technology ProFibrix BV develops and markets products for the hemostasis and regenerative medicine markets. Its product in pipeline, ProFibrix, is a hemostatic agent for mild to moderate surgical bleeding. The firm operates through its offices located in Leiden and Seattle. It is a subsidiary of The Medicines Company. The company was founded in 2004 by Jaap Koopman and is headquartered in Leiden, the Netherlands. | Biotechnology | Director/Board Member Director/Board Member | |
| Index Ventures (UK) LLP | Investment Managers | Private Equity Investor Private Equity Investor | |
Life Sciences Development Campus NV
 Life Sciences Development Campus NV Miscellaneous Commercial ServicesCommercial Services Life Sciences Development Campus NV provides research and development services in the field of biomedical life sciences. The company is headquartered in Abis, BelGium. | Miscellaneous Commercial Services | Director/Board Member | |
V&V Invest BV /BE/
 V&V Invest BV /BE/ Real Estate DevelopmentFinance V&V Invest BV is a residential construction company based in Hasselt, Belgium. and has subsidiaries in Belgium. The Belgian company specializes in developing residential construction projects. | Real Estate Development | Director/Board Member | |
| Hogeschool-Universiteit Brussel | College/University | Graduate Degree | |
Amakem NV
 Amakem NV Medical/Nursing ServicesHealth Services Amakem NV operates as a biopharmaceutical company. It uses kinase inhibitors for treatments of bowel, eye, and lung diseases. The company was founded by Jack Elands, Dirk Leysen, Olivier Raynald Defert, and Nadya Kaval on July 22, 2009 and is headquartered in Diepenbeek, Belgium. | Medical/Nursing Services | Director/Board Member | |
Mind-NRG SARL
 Mind-NRG SARL Medical/Nursing ServicesHealth Services Mind-NRG SARL specializes in research and development programs with focus on the treatment psychiatric and neurologic diseases. The company was founded in 2010 and is headquartered in Geneva, Switzerland. | Medical/Nursing Services | President Chairman Director/Board Member | |
Fast Forward Pharmaceuticals BV
 Fast Forward Pharmaceuticals BV Medical SpecialtiesHealth Technology Fast Forward Pharmaceuticals BV develops novel disease-modifying therapeutics for the treatment of inflammatory and autoimmune diseases. It is developing an anti-CD40 monoclonal antibody therapy for the treatment of chronic inflammatory diseases like primary biliary cirrhosis and Crohn’s disease. The company was founded by Louis Boon in October 2010 and is headquartered in Utrecht, Netherlands. | Medical Specialties | Director/Board Member | |
Xenikos BV
 Xenikos BV Medical SpecialtiesHealth Technology Xenikos BV focuses on the development of immunotherapies for the treatment of patients suffering from immune diseases. It is developing a combination of two toxin-loaded anti-T-cell antibodies, T-Guard, as a therapeutic tool for resetting the body's immune system in T-cell mediated diseases. The company was founded by Ypek van Oosterhout in September 2009 and is headquartered in Nijmegen, the Netherlands. | Medical Specialties | Director/Board Member Director/Board Member | |
| The Wharton School of the University of Pennsylvania | College/University | Masters Business Admin Masters Business Admin | |
| Harvard Business School | College/University | Masters Business Admin Masters Business Admin | |
| SPARK THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
Medicxi Ventures (Jersey) Ltd.
 Medicxi Ventures (Jersey) Ltd. Investment ManagersFinance Medicxi Ventures (Jersey) Ltd. (Medicxi) is an independent venture capital firm founded in 2016 by Francesco de Rubertis, Michèle Ollier, and Kevin S. Johnson. The firm is headquartered in London. | Investment Managers | Founder Founder Founder Private Equity Investor Private Equity Analyst | |
Gadeta BV
 Gadeta BV Medical SpecialtiesHealth Technology Gadeta BV discovers and develops novel cancer immunotherapies. It provides groundbreaking discoveries regarding the role of cell receptors in the broad of heamatological and solid tumor cells. The firm develops t-cells engineered to express a defined gamma delta, an anti- cancer product that eradicates tumors. The company was founded by Jurgen Kuball in 2015 and is headquartered in Utrecht, Netherlands. | Medical Specialties | Director/Board Member Director/Board Member | |
Janpix Holdings, Inc.
 Janpix Holdings, Inc. Miscellaneous Commercial ServicesCommercial Services Janpix Holdings, Inc. engages in provision of research and experimental development on biotechnology. The company was founded by Patrick T. Gunning and Cortes Pierre and is headquartered in Cambridge, MA. | Miscellaneous Commercial Services | Chief Executive Officer Director/Board Member | |
| Andaz Partners | Corporate Officer/Principal | ||
| Cube Management Co. | Corporate Officer/Principal | ||
Palladio Biosciences, Inc.
 Palladio Biosciences, Inc. BiotechnologyHealth Technology Palladio Biosciences, Inc. develops transformative medicines for orphan diseases. Its pipeline includes Lixivaptan, a selective vasopressin V2 receptor antagonist for the treatment of polycystic kidney disease, a life-threatening genetic disease. The company was founded by Lorenzo Pellegrini in 2015 and is headquartered in Newtown, PA. | Biotechnology | Chief Executive Officer Director/Board Member Director/Board Member | |
UltraHuman Ltd.
 UltraHuman Ltd. Miscellaneous Commercial ServicesCommercial Services UltraHuman Ltd. engages in research and experimental development on biotechnology. The company is headquartered in Sandwich, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Human Antibody Factory Ltd.
 Human Antibody Factory Ltd. BiotechnologyHealth Technology Human Antibody Factory Ltd. provides research and experimental development on biotechnology. The company was founded by David John Grainger and is headquartered in Hatfield, the United Kingdom. | Biotechnology | Director/Board Member |
Statistics
International
| United States | 18 |
| Belgium | 11 |
| United Kingdom | 10 |
| Netherlands | 6 |
| France | 5 |
Sectoral
| Health Technology | 24 |
| Consumer Services | 12 |
| Finance | 6 |
| Commercial Services | 6 |
| Distribution Services | 3 |
Operational
| Director/Board Member | 200 |
| Corporate Officer/Principal | 69 |
| Independent Dir/Board Member | 44 |
| Private Equity Investor | 39 |
| Founder | 30 |
Most connected contacts
| Insiders | |
|---|---|
| Bill Doyle | 38 |
| Francesco de Rubertis | 36 |
| Michèle Ollier | 33 |
| Hans-Peter Hasler | 28 |
| Marc Beer | 25 |
| Giovanni Rizzo | 20 |
| Jeryl Hilleman | 19 |
| Geoff Race | 17 |
| Nico Vandervelpen | 17 |
| Jan van Heek | 15 |
| Lorenzo Pellegrini | 14 |
| Daniel Bach | 13 |
| Jan Hammer | 13 |
| Jonathan Edwards | 12 |
| Devin Smith | 11 |
- Stock Market
- Insiders
- Rémy Henri Luthringer
- Company connections
